<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02499510</url>
  </required_header>
  <id_info>
    <org_study_id>Not_applicable</org_study_id>
    <nct_id>NCT02499510</nct_id>
  </id_info>
  <brief_title>First-in-man Study of Titanium-Nitride Coated Woven-nitinol Peripheral Arterial Stent</brief_title>
  <official_title>First-in-man Study to Assess Efficacy and Safety of a Novel Titanium-Nitride Coated Woven-nitinol Peripheral Arterial Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lifetech Scientific (Shenzhen) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GoldenFlow (Lifetech Scientific, Shenzhen, China) is a novel woven-nitinol stent designed
      to have superior radial strength, flexibility and durability compared to standard nitinol
      stents for femoropopliteal lesions. This is a first-in-man study to evaluate the safety and
      efficacy of GoldenFlow woven-nitinol stent for intraluminal treatment of peripheral vascular
      disease in the femoropopliteal arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endovascular treatment in femoropopliteal segment is the most challenging area due to
      restenosis and stent fracture after endovascular treatment. The titanium-nitride coated
      woven-nitinol peripheral arterial stent system (GoldenFlow, Lifetech Science, Shenzhen,
      China) is designed to have superior radial strength, flexibility and durability to withstand
      the compression, torsion, bending, lengthening and shortening found in femoropopliteal
      disease. Compared to another commercially available woven-nitinol stent, the GoldenFlow stent
      has the potential advantage to be repositionable and is less likely to lengthen during
      deployment. This is a first-in-man study is to evaluate the safety and efficacy of GoldenFlow
      woven-nitinol stent for intraluminal treatment of peripheral vascular disease in de-novo
      femoropopliteal lesions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent binary restenosis of the treated segment</measure>
    <time_frame>at 6 month</time_frame>
    <description>Determined by Duplex ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>intraoperation</time_frame>
    <description>defined as residual diameter stenosis &lt;30%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcomes as assessed by composite of death, index limb amputation and ischemic driven target vessel revacularization</measure>
    <time_frame>30 days</time_frame>
    <description>Composite of death, index limb amputation and ischemic driven target vessel revacularization at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven target vessel revascularization</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent fracture</measure>
    <time_frame>6 months</time_frame>
    <description>defined by plain x-ray</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>GoldenFlow stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Titanium nitrite coated woven nitinol stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GoldenFlow Stent</intervention_name>
    <description>The GoldenFlow stent (Lifetech Science, Shenzhen, China) is a TiN coated self-expanding stent consisting of interwoven nitinol wires braided in a closed cell design. Stents used in this study ranged from 4-12mm in diameter and 20-160mm in length.</description>
    <arm_group_label>GoldenFlow stent</arm_group_label>
    <other_name>Titanium-nitride coated GoldenFlow woven-nitinol stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years

          2. Symptomatic leg ischemia (Rutherford class 2 to 4)

          3. Ankle Brachial Index &lt;0.9

          4. De novo femoropopliteal stenosis (≥70%) or occlusion

          5. Reference diameter 4 and 7mm

          6. Lesion length 4 to 15cm

          7. At least one patent (&lt;50% stenosis) infrapopliteal run-off vessel

          8. The lesion(s) can be successfully crossed with a guidewire and dilated

          9. Patients with bilateral femoropopliteal disease is eligible for enrollment into the
             study

             - Staged contralateral limb procedure can be performed &gt;30 days after index procedure

         10. Able to provide written informed consent and willing to comply with specified
             follow-up evaluation schedule

        Exclusion Criteria:

          1. Tissue loss or gangrene (Rutherford class 5 and 6)

          2. Previous bypass surgery or stenting in target vessel

          3. Untreated aortoiliac or common femoral artery inflow disease &gt;50%

          4. Intervention of ipsilateral lesions during the index procedure or staged intervention
             within 30 days after index procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan Ping Yen Yan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tsz Ling TO</last_name>
    <phone>(852) 2632 1750</phone>
    <email>oliviato@cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <state>New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsz Ling TO</last_name>
      <phone>(852) 2632 1750</phone>
      <email>oliviato@cuhk.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000 Jan;31(1 Pt 2):S1-S296. Review.</citation>
    <PMID>10666287</PMID>
  </reference>
  <reference>
    <citation>Johnston KW. Femoral and popliteal arteries: reanalysis of results of balloon angioplasty. Radiology. 1992 Jun;183(3):767-71.</citation>
    <PMID>1294068</PMID>
  </reference>
  <reference>
    <citation>Minar E, Pokrajac B, Maca T, Ahmadi R, Fellner C, Mittlböck M, Seitz W, Wolfram R, Pötter R. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty : results of a prospective randomized study. Circulation. 2000 Nov 28;102(22):2694-9.</citation>
    <PMID>11094034</PMID>
  </reference>
  <reference>
    <citation>Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation. 1991 Feb;83(2 Suppl):I70-80.</citation>
    <PMID>1825050</PMID>
  </reference>
  <reference>
    <citation>Henry M, Amor M, Beyar R, Henry I, Porte JM, Mentre B, Tricoche O, Ethevenot G. Clinical experience with a new nitinol self-expanding stent in peripheral arteries. J Endovasc Surg. 1996 Nov;3(4):369-79.</citation>
    <PMID>8959493</PMID>
  </reference>
  <reference>
    <citation>Cejna M, Thurnher S, Illiasch H, Horvath W, Waldenberger P, Hornik K, Lammer J. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol. 2001 Jan;12(1):23-31.</citation>
    <PMID>11200349</PMID>
  </reference>
  <reference>
    <citation>Vroegindeweij D, Vos LD, Tielbeek AV, Buth J, vd Bosch HC. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: A comparative randomized study. Cardiovasc Intervent Radiol. 1997 Nov-Dec;20(6):420-5.</citation>
    <PMID>9354709</PMID>
  </reference>
  <reference>
    <citation>Grimm J, Müller-Hülsbeck S, Jahnke T, Hilbert C, Brossmann J, Heller M. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol. 2001 Aug;12(8):935-42.</citation>
    <PMID>11487673</PMID>
  </reference>
  <reference>
    <citation>Zdanowski Z, Albrechtsson U, Lundin A, Jonung T, Ribbe E, Thörne J, Norgren L. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions? A randomized controlled study. Int Angiol. 1999 Dec;18(4):251-5.</citation>
    <PMID>10811511</PMID>
  </reference>
  <reference>
    <citation>Becquemin JP, Favre JP, Marzelle J, Nemoz C, Corsin C, Leizorovicz A. Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. J Vasc Surg. 2003 Mar;37(3):487-94.</citation>
    <PMID>12618680</PMID>
  </reference>
  <reference>
    <citation>Schillinger M, Minar E. Endovascular stent implantation for treatment of peripheral artery disease. Eur J Clin Invest. 2007 Mar;37(3):165-70.</citation>
    <PMID>17359483</PMID>
  </reference>
  <reference>
    <citation>Tetteroo E, van der Graaf Y, Bosch JL, van Engelen AD, Hunink MG, Eikelboom BC, Mali WP. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group. Lancet. 1998 Apr 18;351(9110):1153-9.</citation>
    <PMID>9643685</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Professor Bryan Ping Yen YAN</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>femoropopliteal disease</keyword>
  <keyword>restenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

